Optimizing Advances in Nanoparticle Delivery for Cancer Immunotherapy.
Cancer Immunotherapy
Immunotherapy
Nanomedicine
Nanoparticle
Journal
Advanced drug delivery reviews
ISSN: 1872-8294
Titre abrégé: Adv Drug Deliv Rev
Pays: Netherlands
ID NLM: 8710523
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
17
05
2019
revised:
10
07
2019
accepted:
12
07
2019
pubmed:
23
7
2019
medline:
17
6
2020
entrez:
23
7
2019
Statut:
ppublish
Résumé
Cancer immunotherapy is one of the fastest growing and most promising fields in clinical oncology. T-cell checkpoint inhibitors are revolutionizing the management of advanced cancers including non-small cell lung cancer and melanoma. Unfortunately, many common cancers are not responsive to these drugs and resistance remains problematic. A growing number of novel cancer immunotherapies have been discovered but their clinical translation has been limited by shortcomings of conventional drug delivery. Immune signaling is tightly-regulated and often requires simultaneous or near-simultaneous activation of multiple signals in specific subpopulations of immune cells. Nucleic acid therapies, which require intact intracellular delivery, are among the most promising approaches to modulate the tumor microenvironment to a pro-immunogenic phenotype. Advanced nanomedicines can be precisely engineered to overcome many of these limitations and appear well-poised to enable the clinical translation of promising cancer immunotherapies.
Identifiants
pubmed: 31330165
pii: S0169-409X(19)30119-X
doi: 10.1016/j.addr.2019.07.009
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3-15Subventions
Organisme : NCI NIH HHS
ID : U54 CA198999
Pays : United States
Organisme : NIBIB NIH HHS
ID : R01 EB025651
Pays : United States
Informations de copyright
Copyright © 2019. Published by Elsevier B.V.